Co., Ltd. 
Marketing supported by Eisai Co., Ltd.

Glossary

1. Automated Clinical Chemistry Analyser

A device mainly for colorimetric analysis of marker in serum or plasma using enzyme reaction or colour reaction. The process from sampling to output of assay result is automated. Although discrete method is widely used currently, electrolyte test by electrode method and immunological test by latex immunoturbidimetric assay can also be done using this analyser.

2. Latex Immunoturbidimetric Assay

Latex particles that have sensitised antibody and antigen in specimen cause antigen-antibody reaction to agglutinate latex particles. This assay determines the agglutination as a change of absorbance. Reagent for latex immunoturbidimetry is widely used as the agglutination of latex particles can be determined quantitatively with an easy operation of the automated clinical chemistry analyser.

3. Interstitial Pneumonia

Human lungs are made up of multiple, small grape-like structures called alveoli, where the exchange of oxygen and carbon dioxide takes place. Inflammation of alveoli causes pneumonia, which can be roughly classified into two groups based on the region where the inflammation occurs: interstitial pneumonia, in which inflammation occurs in the walls of the alveoli (interstitium), and alveolar pneumonia (commonly-termed pneumonia), in which inflammation occurs in the airway between bronchi and alveoli (alveolar space). Differential diagnosis is required since treatment for these two types of pneumonia is different. 

4. KL-6 (Sialylated Carbohydrate Antigen)

KL-6 is expressed on the surface of type II alveolar epithelial cells which consist of the walls of the alveolus (interstitium). In interstitial pneumonia, type II alveolar epithelial cells are excessively formed and the KL-6 level increases. Determination of serum KL-6 level is effective for the diagnosis of interstitial pneumonia since intracellular KL-6 exudes into blood. 



		
				


				About Eisai


			Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

		




Contact:


Eisai Co., Ltd.
Public Relations
Phone: +81-3-3817-5120

Sanko Junyaku Co., Ltd.
Public Relations
Phone: +81-3-3865-4311

Sekisui Medical Co., Ltd.
General Affairs Group
General Affairs
& Personnel Department
Phone: +81-3-3272-0672

			 
 

  

	

June 1, 2009
Source: Eisai
Eisai (TSE: 4523) (U.S: ESALY)
			
From the Japan Corporate News Network
			
http://www.japancorp.net
			
Topic: New Product


		


Copyright © 2013 JCN Newswire. All rights reserved. A division of Japan Corporate News Network KK.